Cannabinoid formulation for oral administration
AssigneeCb21 Pharma, S.R.O.
InventorsAntonin MALIK, Jan STORCH
Life of this patent
Estimating the term…
Abstract
A pharmaceutical formulation contains a particulate porous sorbent selected from the group having aluminosilicates and their salts, with a neutral or basic pH and with a particle size in the range of 50 to 800 μm, on which a mixture of polyoxyethylene sorbitan monooleate (Polysorbate 80) with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC and D8-THC is applied. The formulation improves bioavailability and releases profile of the cannabinoids.
Claims14
A pharmaceutical formulation, comprising a particulate porous sorbent selected from a group of aluminosilicates and their salts, with a particle size in the range of 50 to 800 pm, on which a mixture of polyoxyethylene sorbitan monooleate with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC and D8-THC is applied.
Dependencies are inferred from the claim text.